Bimekizumab versus Adalimumab in Plaque Psoriasis

To the Editor: The trial reported by Warren and colleagues (July 8 issue) 1 showed that bimekizumab was superior to adalimumab in reducing cutaneous symptoms of plaque psoriasis but was associated with a higher incidence of oral candidiasis and diarrhea. The prevalence of psoriasis among persons 20 years of age or older is reported to be higher among Whites (78.5%) than among Blacks (5.0%) and Hispanics (8.6%). 2 In the trial by Warren et al., 88.1% of the patients were White, with minimal representation of Blacks and other minorities. Although the severity of psoriasis among Blacks and Hispanics is similar to that . . .